CCG
TGTX icon

Capital CS Group’s TG Therapeutics TGTX Stock Holding History

Capital CS Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,600
Closed -$141K – 129
2023
Q4 		$141K Buy
+10,600
New +$123K 0.15% 62
2021
Q4 		– Sell
-4,700
Closed -$57K – 92
2021
Q3 		$57K Buy
+4,700
New +$145K 0.05% 62

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital CS Group's TGTX Position: Q4 2024 in Review

Capital CS Group sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 17,525 shares — an estimated $410K sold.

Capital CS Group first reported a position in TGTX in Q3 2021 and held it in 13 quarters. The position peaked at $591K in Q3 2021. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Capital CS Group reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital CS Group sold 17,525 TG Therapeutics shares in Q4 2024, an estimated $410K.
  • Capital CS Group first reported a position in TG Therapeutics in Q3 2021 and held it in 13 quarters.
  • Capital CS Group's TG Therapeutics position peaked at $591K in Q3 2021.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Capital CS Group's 13F filing for Q4 2024, filed 14 Jan 2025.